The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Antiarrhythmic Actions of Intravenous Ibutilide Compared With Procainamide During Human Atrial Flutter and Fibrillation: Electrophysiological Determinants of Enhanced Conversion Efficacy
Abstract
BACKGROUND: The selective class III antiarrhythmic agent ibutilide prolongs action potential duration and terminates atrial flutter (AFL) and fibrillation (AF), but the mechanism of its antiarrhythmic efficacy in humans has not been fully characterized. This study compared the antiarrhythmic effects of ibutilide with the class IA agent procainamide in humans during AFL and AF. Antiarrhythmic drug actions and electrophysiological characteristics of AFL and AF that enhanced pharmacological termination were investigated. METHODS AND RESULTS: Right atrial monophasic action potentials were recorded during 148 episodes of AFL (n=89) or AF (n=59) in 136 patients treated with intravenous ibutilide (n=73) or placebo (n=22) as participants in randomized, double-blinded comparative studies or intravenous procainamide (n=53) in a concurrent open-label study. The conversion rates in AFL with ibutilide, procainamide, and placebo were 64% (29 of 45 patients), 0% (0 of 33), and 0% (0 of 11), respectively, whereas in AF the rates were 32% (9 of 28), 5% (1 of 20), and 0% (0 of 11), respectively. In AFL, ibutilide increased atrial monophasic action potential duration (MAPD) more (30% versus 18%, P<.001) and prolonged atrial cycle length (CL) less (16% versus 26%, P<.001) than procainamide. Ibutilide shortened and procainamide prolonged action potential diastolic interval during AFL (-12% versus 51%, P<.001). Ibutilide increased MAPD/CL ratio, whereas procainamide tended to decrease this ratio (13% versus -6%, P<.01). In AF, ibutilide and procainamide induced similar increases in atrial CL (48% versus 45%), but ibutilide induced a greater increase in MAPD (52% versus 37%, P<.05). Independent electrophysiological predictors of pharmacological arrhythmia termination were increase in MAPD/CL ratio (P=.005) in AFL and longer baseline mean MAPD (P=.011) in AF. Termination of AFL with ibutilide was characterized by significant increases in beat-to-beat atrial CL, MAPD, and diastolic interval variability. Ibutilide was significantly more effective in converting AF when the mean atrial CL was > or = 160 ms (64% versus 0%, P<.001) or MAPD was > or = 125 ms (57% versus 0%, P=.002) at baseline. CONCLUSIONS: Enhanced conversion efficacy of ibutilide compared with procainamide in AFL is correlated with a relatively greater prolongation of atrial MAPD than atrial CL, and termination of AFL by ibutilide is characterized by oscillations in atrial CL and MAPD. Conversion of AF by ibutilide is enhanced by a longer baseline mean atrial CL or MAPD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dofetilide and ibutilide, pure class III AADs, are very effective for interrupting AFL in intravenous administration, while Class Ia and Ic drugs have little or no effect.138 -142,149”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [140]
Citations
Cites
High-density mapping of electrically induced atrial fibrillation in humans.
Konings, K., Kirchhof, C. J. H. J., Smeets, J. L. R. M., Wellens, H. J. J., Penn, O. C. K. M., & Allessie, M. A. (1994) · Circulation · doi:10.1161/01.cir.89.4.1665 · Cited by 959
On the multiple wavelet hypothesis o f atrial fibrillation.
Moe, G. K. (1962) · Medical Entomology and Zoology · Cited by 714
Rensma, P., Allessie, M., Lammers, W., Bonke, F. I., & Schalij, M. (1988) · Circulation Research · doi:10.1161/01.res.62.2.395 · Cited by 686
Stambler, B. S., Wood, M. A., Ellenbogen, K. A., Perry, K. T., Wakefield, L. K., & VanderLugt, J. T. (1996) · Circulation · doi:10.1161/01.cir.94.7.1613 · Cited by 485
Self-citationEllenbogen, K. A., Stambler, B. S., Wood, M. A., Sager, P. T., Wesley, R. C., Meissner, M. D., Zoble, R. G., Wakefield, L. K., Perry, K. T., VanderLugt, J. T., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00121-0 · Cited by 370
Self-citationCharacterization of Atrial Fibrillation in Man: Studies Following Open Heart Surgery*
WELLS, J. L., Karp, R. B., Kouchoukos, N. T., MacLean, W. A. H., James, T. N., & Waldo, A. L. (1978) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1978.tb03504.x · Cited by 291
Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.
Wang, Z., Pagé, P., & Nattel, S. (1992) · Circulation Research · doi:10.1161/01.res.71.2.271 · Cited by 225
Wang, J., Bourne, G. W., Wang, Z., VILLEMAIRE, C., Talajic, M. R., & Nattel, S. (1993) · Circulation · doi:10.1161/01.cir.88.3.1030 · Cited by 209
Yang, T., Snyders, D. J., & Roden, D. M. (1995) · Circulation · doi:10.1161/01.cir.91.6.1799 · Cited by 193
Research works printed but not linked: 13
- 10.1161/circ.74.1.3708774 · DOI
- 10.1161/circ.76.6.2445503 · DOI
- 10.1161/res.65.6.2510953 · DOI
- 10.1161/res.68.4.2009611 · DOI
- 10.1161/res.71.2.1628386 · DOI
- Feld GK. Pharmacological control of experimental atrial arrhythmias: significance of prolonging excitation wavelength. In: Singh BN Wellens HJJ Hiraoka M eds. Electropharmacological Control of Cardiac Arrhythmias to Delay Conduction or to Prolong Refractoriness? Mount Kisco NY: Futura Publishing Co; 1994:265-277.
- Allessie MA. Reentrant mechanisms underlying atrial fibrillation. In: Zipes DP Jalife J eds. Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia Pa: WB Saunders Co; 1995:562-566.
- 10.1161/circ.94.7.1613 · DOI
- Volgman AS, Stambler BS, Kappagoda C, Carberry PA, Dunn GH, Perry KT, VanderLugt JT, Kowey PR. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter. PACE. 1996;19:608. Abstract.
- 10.1161/circ.46.3.528 · DOI
- Lammers WJEP, Allessie MA, Rensma PL. The use of fibrillation cycle length to determine spatial dispersion in electrophysiological properties and to characterize the underlying mechanisms of fibrillation. New Trends Arrhythmias. 1986;2:109-112.
- Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther. 1962;140:183-188.
- Buchanan LV, LeMay RJ, Gibson JK. Comparison of the class III agents d,l-sotalol HCl and ibutilide fumarate for atrial reverse use dependence and antiarrhythmic effects. PACE. 1996;19:687. Abstract.
Cited by
Sorted by citations
Items 101–155 of 155
Review : Pharmacological Management of Atrial Fibrillation: An Update
Hohnloser, S. H., Li, Y., Bender, B., & Grönefeld, G. (2000) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840000500102 · Cited by 6
Sun, H., Velipasaoglu, E., Berrier, K. L., & Khoury, D. S. (1998) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1998.tb01208.x · Cited by 6
Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter
Amadori, M., Rapacciuolo, A., & Diemberger, I. (2022) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2022.05.006 · Cited by 5
Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, L., Despres, C., Dickstein, K., Lekakis, J. P., McGregor, K., Metra, M., Budaj, A., et al. (2006) · Cited by 5
Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.
Sharma, P. S., & Callans, D. J. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.740 · Cited by 5
Bollmann, A., Sonne, K., WODARZ, K., Esperer, H.-D., Toepffer, I., & Klein, H. (2003) · Computers in cardiology · doi:10.1109/cic.1999.826066 · Cited by 5
Melikian, N., Brookes, C. I. O., & Rickards, A. F. (1999) · Heart · doi:10.1136/hrt.82.2.182 · Cited by 5
Frequency Analysis of Atrial Fibrillation Predicts Success for Low Energy Intracardiac Cardioversion
Díaz, J., Escalona, O. J., Anderson, J. M., Glover, B., & Adgey, A. A. J. (2007) · Springer eBooks · doi:10.1007/978-3-540-36841-0_242 · Cited by 4
Class III Antiarrhythmic Drugs
Tamargo, J. L., Caballero, R., & Delpón, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-34893-9_3 · Cited by 4
Morita, N., Kobayashi, Y., Iwasaki, Y., Hayashi, M., Miyauchi, Y., Atarashi, H., Tanaka, K., Katoh, T., & Mizuno, K. (2008) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2008.01120.x · Cited by 4
Raitt, M. H., & Kusumoto, W. (2012) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2011.12.006 · Cited by 4
Atrial Remodelling : Role in Atrial Fibrillation Ablation.
Grubitzsch, H., & Haverkamp, W. (2012) · Europe PMC (PubMed Central) · doi:10.4022/jafib.691 · Cited by 4
Stambler, B. S. (1998) · Cardiac Electrophysiology Review · doi:10.1023/a:1009967713885 · Cited by 4
Self-citationBurashnikov, A. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1447542 · Cited by 3
Management Strategies in Atrial Fibrillation in Patients With Heart Failure
Shaikh, A. Y., Maan, A., Heist, E. K., Tighe, D. A., Aurigemma, G. P., & McManus, D. D. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31825dcf9b · Cited by 3
Santini, M., Pignalberi, C., Ricci, R. P., Calò, L., & Santini, L. (2003) · Journal of Interventional Cardiac Electrophysiology · doi:10.1023/a:1025360202173 · Cited by 3
Frequenz- und Rhythmuskontrolle bei Vorhofflimmern
Weipert, K. F., Erkapic, D., & Schmitt, J. (2015) · Herz · doi:10.1007/s00059-014-4201-3 · Cited by 3
ADVANCES IN CARDIAC ELECTROPHYSIOLOGY AND PACING
Lü, F., & Trohman, R. G. (2001) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70171-8 · Cited by 3
Atrial activity estimation using periodic component analysis
Llinares, R., Igual, J., Miró-Borrás, J., & Camacho-García, A. (2010) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn.2010.5596951 · Cited by 3
Ellenbogen, K. A., Wood, M. A., & Gilligan, D. M. (1998) · Cardiac Electrophysiology Review · doi:10.1023/a:1009971814794 · Cited by 3
Self-citationOral, H., Knight, B. P., Sticherling, C., Kim, M. H., Baker, R. L., Chough, S. P., Wasmer, K., Pelosi, F., Michaud, G. F., Fendrick, A. M., et al. (2000) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1054/jcpt.2000.16696 · Cited by 3
Atrial fibrillation in pregnancy
Georgiopoulos, G. A., Margioula, E., O’Neill, L., & Chatzidou, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817728-0.00061-9 · Cited by 2
Zeng, Z., Wang, L., Hua, L., Jiang, J., Pang, H., Huang, Y., Li, Y., & Tian, L. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.349 · Cited by 2
Does targeting ibutilide-resistant CFAE improve outcomes for catheter ablation of persistent AF?
Shah, D. C. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw109 · Cited by 2
Camm, A. J., Kirchhof, P. F., Ernst, S., Gelder, I. C. V., Hindricks, G., Heidbüchel, H., Colonna, P., Goette, A., Hohloser, S. H., Kolh, P. H., et al. (2010) · Cited by 2
Atrial Activity Extraction Based on Statistical and Spectral Features
Llinares, R., Igual, J., Salazar, A., Miró-Borrás, J., & Serrano, A. (2009) · Lecture notes in computer science · doi:10.1007/978-3-642-00599-2_57 · Cited by 1
Pharmacologic targets for atrial fibrillation
Bhakta, D., & Miller, J. M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1161 · Cited by 1
Update on Intravenous Ibutilide
Stambler, B. S. (2000) · Cardiac Electrophysiology Review · doi:10.1023/a:1026539330714 · Cited by 1
Self-citationGessman, L. J., & Trohman, R. G. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50034-0 · Cited by 1
Amiodarone and the Excitable Gap:
Akar, J. G., & Wilber, D. J. (2004) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2004.04679.x · Cited by 1
Pitzalis, M. V., Grimaldi, M., Anaclerio, M., Iacoviello, M., Luzzi, G., Forleo, C., & RIZZON, P. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01510-1 · Cited by 1
Bollmann, A., Klein, H., & Esperer, H.-D. (2000) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s003990070042 · Cited by 1
Penny-Peterson, E., & Naccarelli, G. V. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch39 · Cited by 1
The Management of Atrial Flutter
Rho, R. W., & Callans, D. J. (2002) · Contemporary cardiology · doi:10.1007/978-1-59259-090-2_9
Themistoclakis, S., Bonso, A., Rossillo, A., Corrado, A., GASPARINI, G., Raviele, A., & Scheinman, M. M. (2002) · Springer eBooks · doi:10.1007/978-88-470-2103-7_59
Complications during vascular surgery: basic principles and management of arrhythmias
Teplick, R. S. (2000) · Best practice & research. Clinical anaesthesiology · doi:10.1053/bean.2000.0063
Review of the current management of atrial fibrillation
Gould, P. A., Power, J., Broughton, A., & Kaye, D. M. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1889
Feld, G. K. (2000) · Developments in cardiovascular medicine · doi:10.1007/978-0-585-28007-3_1
Maury, P., Fourcade, J., Duparc, A., Mondoly, P., Rollin, A., Détis, N., HEBRARD, A., Delay, M., Elbaz, M., Carrié, D., et al. (2010) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2010.10.008
Ellenbogen, K. A. (1999) · Evidence-based Cardiovascular Medicine · doi:10.1054/ebcm.1999.0246
Self-citationESC COMMITTEE FOR PRACTICE GUIDELINES & POLICY CONFERENCES MEMBERS
Fuster, V., Wann, L. S., McNamara, R. L., Prystowsky, E. N., Gibbons, R. J., Antman, E. M., Alpert, J. S., & Gregoratos, G. (2001)
Jia, R. (2012) · Otago University Research Archive (University of Otago)
The effect of internal DC shocks on the atrial fibrillation frequency
Díaz, J., Castro, N. C., Escalona, O. J., Anderson, J., Glover, B. M., & Adgey, J. (2007) · Conference proceedings · doi:10.1109/iembs.2007.4352859
Pharmacotherapy of Atrial Fibrillation
Chevalier, P., & Touboul, P. (1998) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.1998.tb00414.x
Review Article Frequency Analysis of Atrial Fibrillation From the Surface Electrocardiogram
Husser, D., Stridh, M., Sörnmo, L., Olsson, S. B., & Bollmann, A. (2004)
Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.
Talajic, M. R., & Roy, D. (2005) · PubMed
Too Fast for Comfort: Tachycardia in Postablation Wolff-Parkinson-White
Ling, E., Stayton, T. L., Stripe, B. R., Srivatsa, U. N., Amsterdam, E. A., & Venugopal, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.026
Pharmacologic Management of Atrial Fibrillation
Finkle, J. K., Plunkitt, K., & Kowey, P. R. (2002) · Contemporary cardiology · doi:10.1007/978-1-59259-090-2_6
Treatment of Acute Atrial Fibrillation: Ventricular Rate Control and Restoration of Sinus Rhythm
Fung, H., & Kam, C. W. (2000) · Hong Kong Journal of Emergency Medicine · doi:10.1177/102490790000700205 · Cited by 1
Common Atrial and Ventricular Arrhythmias
Foreman, B. W. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_23
Fulton, S., & Jackimczyk, K. C. (2000) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(05)70152-8
Paciullo, C. A. (2011) · Springer eBooks · doi:10.1007/978-0-85729-606-1_7
Common Atrial and Ventricular Arrhythmias
Foreman, B. W. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-963-5_24
Class III Antiarrhythmic Drugs
Delpón, E., Caballero, R., & Tamargo, J. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_5 · Cited by 1
Hu, G. J., & O’Kane, C. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_13
Metadata
- Authors
- Stambler, B. S., Wood, M. A., & Ellenbogen, K. A.
- Affiliations
- Harvard University (US)
- Venue
- Circulation
- Published
- 1997-12-16
- Volume
- 96
- Issue
- 12
- Pages
- 4298-4306
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2060841225
- Cited by
- 156
- References
- 35
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 6
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- ibutilide, procainamide, atrial flutter, atrial fibrillation, antiarrhythmic drugs, class III antiarrhythmic agents, monophasic action potential duration, atrial cycle length, intravenous administration
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Electrophysiology, Female, Humans, Injections, Intravenous, Male, Middle Aged, Procainamide, Sulfonamides, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
